Dr. Townson heads development programs for Immuno-oncology and Cell Therapy assets at Bayer.
Dr. Townson’s current development activities include: AhR-inhibition, DGK-inhibition, and allogeneic CAR-T treatment. In the past several years Dr. Townson’s successes include the global registration and launch of hematology and cell therapy assets as well as multiple INDs and early clinical testing of novel small-molecule and anti-body check-point therapies.